Access to Birth Control Act
- Bill Number
- S. 2302
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-08-01: Star Print ordered on the bill.
- Last Updated
- 2026-01-29T12:03:18Z
AI-Generated Summary
Purpose
The Access to Birth Control Act (S. 2302) aims to ensure reliable access to Food and Drug Administration (FDA)-approved contraception and related medications by imposing specific duties on pharmacies. It addresses barriers to birth control, such as refusals by pharmacists due to personal beliefs, and promotes reproductive health equity, particularly for underserved communities facing systemic inequities like racism and discrimination.
Key Provisions
- Pharmacy Duties: Pharmacies that handle FDA-approved drugs or devices must:
- Provide in-stock contraceptives (drugs or devices to prevent pregnancy) or related medications (those needed before or with contraception, as determined by a medical professional) immediately upon request.
- If not in stock but typically stocked in normal business operations, inform the customer right away and offer options: refer or transfer the prescription to another pharmacy with the item available, or order it using the pharmacy's standard expedited process and notify the customer when ready.
- Prohibited Practices: Pharmacies must prevent:
- Intimidation, threats, or harassment of customers seeking these items.
- Employee interference, obstruction, or intentional misinformation about availability or how the products work.
- Breaches of medical privacy or threats to do so.
- Refusals to return a valid prescription upon request.
- Exceptions:
- Pharmacies not ordinarily stocking these items are exempt from ordering requirements.
- Refusals are allowed if: the item requires a prescription that's not provided (and it's illegal without one); the customer can't pay; or an employee uses professional clinical judgment (applying medical knowledge based on standard practices) to decline.
- Enforcement:
- Civil penalties up to $1,000 per day of violation, capped at $100,000 per case, enforced by the U.S. government.
- Private lawsuits by affected individuals for damages, court orders to stop violations, and attorney fees; suits must start within 5 years.
- Definitions (key terms explained):
- Contraception: FDA-approved drugs or devices to prevent pregnancy.
- Pharmacy: State-licensed retail sellers of prescription drugs with employees.
- Without delay: Within the pharmacy's usual timeframe for similar services.
- Other Rules:
- Does not override stronger state laws or professional standards for pharmacies.
- Takes effect 31 days after enactment, no need for federal guidance first.
- Preserves rights under Title VII of the Civil Rights Act of 1964 (which prohibits employment discrimination); the Religious Freedom Restoration Act (RFRA, a law protecting religious practices) cannot be used as a defense or challenge to this law.
Significant Changes to Existing Law
This bill adds a new section (SEC. 249) to Part B of Title II of the Public Health Service Act (a major federal health law). It introduces federal mandates on pharmacies to prioritize access to contraception, going beyond current guidelines (like those from the Department of Health and Human Services on sex discrimination). It explicitly limits refusals based on personal beliefs, responding to increased denials reported after the 2022 Supreme Court decision in Dobbs v. Jackson Women's Health Organization (which ended federal abortion rights). Previously, such refusals were handled variably by states or under anti-discrimination rules, but this creates uniform national duties with enforcement tools.
Potential Impacts
- On Citizens: Improves access to birth control for about 58 million insured women and others, potentially reducing unintended pregnancies (which affected 42% of U.S. pregnancies in 2019) and supporting health needs like treating endometriosis or irregular periods. It could benefit marginalized groups (e.g., low-income Hispanic women with 58% unintended pregnancy rates vs. 33% for White women) by reducing barriers like stigma, cost, and discrimination.
- On Government Agencies: The Department of Health and Human Services (HHS) and FDA may see increased roles in enforcement and monitoring compliance, though no new funding is specified. States retain authority for licensing pharmacists.
- On Pharmacies and Businesses: Requires operational changes, such as better stocking, staff training, and referral systems, which could raise costs but ensure consistent service. Large chains may adapt easily, while small or rural pharmacies might face challenges.
- On International Relations: Minimal direct impact, though it reinforces U.S. commitments to global reproductive health standards.
Main Stakeholders Affected
- Customers: Primarily women and sexually active individuals seeking contraception, especially those in underserved communities (e.g., racial minorities, low-income groups, immigrants) facing higher barriers.
- Pharmacies and Pharmacists: Retail drug sellers and their employees, who must comply or risk penalties; individual refusals based on beliefs are curtailed except for clinical reasons.
- Healthcare Providers: Doctors and clinics, as the law supports their prescriptions and reduces access hurdles for patients.
- Government Entities: HHS for enforcement; FDA for product approvals; state licensing boards for complementary rules.
- Advocacy Groups: Organizations focused on reproductive rights, civil rights, and health equity, who may use private lawsuits to ensure compliance.
Notable Legal, Constitutional, or Political Implications
- Legal: Creates a private right of action (allowing individuals to sue directly in court), strengthening enforcement beyond government action alone. Aligns with existing anti-discrimination laws (e.g., under the Affordable Care Act) by treating contraception refusals as potential sex discrimination.
- Constitutional: Balances reproductive rights (recognized as fundamental, per congressional findings) with limited exceptions for professional judgment, avoiding broad conflicts with free exercise of religion by restricting RFRA's application. It does not directly address First Amendment concerns but could face challenges on religious liberty grounds.
- Political: Introduced by a bipartisan group of senators, it highlights post-Dobbs tensions over reproductive access without touching abortion. It promotes equity by citing systemic racism and could influence state policies, potentially sparking debates on federal vs. state authority in health care.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (25)
Sen. Murray, Patty [D-WA], Sen. Shaheen, Jeanne [D-NH], Sen. Baldwin, Tammy [D-WI], Sen. Kaine, Tim [D-VA], Sen. Blumenthal, Richard [D-CT], Sen. Duckworth, Tammy [D-IL], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Warner, Mark R. [D-VA], Sen. Rosen, Jacky [D-NV], Sen. Whitehouse, Sheldon [D-RI], Sen. Heinrich, Martin [D-NM], Sen. Smith, Tina [D-MN], Sen. Hirono, Mazie K. [D-HI], Sen. Schiff, Adam B. [D-CA], Sen. Warren, Elizabeth [D-MA], Sen. Wyden, Ron [D-OR], Sen. Markey, Edward J. [D-MA], Sen. Merkley, Jeff [D-OR], Sen. Van Hollen, Chris [D-MD], Sen. Alsobrooks, Angela D. [D-MD], Sen. Padilla, Alex [D-CA], Sen. Klobuchar, Amy [D-MN], Sen. Murphy, Christopher [D-CT], Sen. Kim, Andy [D-NJ], Sen. Coons, Christopher A. [D-DE]
Recent Actions
- 2025-08-01: Star Print ordered on the bill.
- 2025-07-16: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-07-16: Introduced in Senate
Bill Versions
- Access to Birth Control Act — issued 2025-07-16 — PDF (13 pages)